Microdose Semaglutide vs Tirzepatide: What the Lowest Doses in the Trials Actually Show

People weighing microdose semaglutide vs tirzepatide usually want a short answer: which one does more at a small dose, with fewer side effects? The honest short answer is that nobody knows, because no trial has tested either drug as a long-term microdose for weight loss, let alone compared them at low doses.

The longer answer is more useful. Semaglutide was once tested at daily doses far below today's weekly schedule. Tirzepatide was tested at 1 mg a week before its approved doses were set. And two large trials, SURPASS-2 and SURMOUNT-5, put the drugs side by side. This article walks through each, then covers the practical questions people ask: half-life, refrigeration, and how these drugs are actually obtained. For the broader comparison at standard doses, see our earlier guide to semaglutide vs tirzepatide.

What is considered a microdose of semaglutide or tirzepatide?

A microdose of semaglutide or tirzepatide has no official definition. In practice, the term describes weekly doses below each drug's labeled starting dose, taken for a longer stretch than the label's four-week starter step. No regulator, guideline or trial uses the word.

The labels set the reference points. The Wegovy prescribing information starts semaglutide at 0.25 mg once weekly for weeks 1 to 4, then steps through 0.5 mg, 1 mg and 1.7 mg, with 1.7 mg or 2.4 mg as maintenance for weight reduction in adults. The Zepbound prescribing information starts tirzepatide at 2.5 mg once weekly for 4 weeks and states that 2.5 mg "is for treatment initiation and is not approved as a maintenance dosage." Its maintenance doses for weight reduction are 5 mg, 10 mg or 15 mg.

So "microdose semaglutide" generally means something under 0.25 mg a week, and "microdose tirzepatide" something under 2.5 mg a week. Those are very different numbers on paper, which leads to the most common mistake in this comparison.

Why can't you compare semaglutide and tirzepatide milligram for milligram?

Semaglutide and tirzepatide milligrams cannot be compared directly because they are different molecules with different potencies, and each label was built on its own dose scale. A 2.5 mg tirzepatide starting dose is not "more drug" in any useful sense than a 0.25 mg semaglutide starting dose. Both are the gentlest step each manufacturer chose for its own molecule.

The receptors differ too. Semaglutide acts on the GLP-1 receptor alone. Tirzepatide acts on both the GIP and GLP-1 receptors, and the Zepbound label notes that GLP-1 is "a physiological regulator of appetite and caloric intake." That dual action is the usual explanation for tirzepatide's larger effect at full doses, though how the two receptors share the work at small doses has not been studied in people.

The practical point: a "tirzepatide microdose" and a "semaglutide microdose" with the same number on the vial are not equivalent, and percentages of a label dose are not equivalent either. Any conversion between them is guesswork unless a prescriber is working from something firmer.

Does microdose semaglutide work?

Microdose semaglutide has not been tested for weight loss, so whether it works is not established. The closest data come from a phase 2 trial by O'Neil and colleagues, published in the Lancet in 2018. It gave 957 adults without diabetes, with a mean starting weight of 111.5 kg, one of five once-daily semaglutide doses or placebo for 52 weeks.

Weight loss was 2.3% on placebo, 6.0% on 0.05 mg a day, 8.6% on 0.1 mg, 11.6% on 0.2 mg, 11.2% on 0.3 mg and 13.8% on 0.4 mg. The authors reported that the most common adverse events were "dose-related gastrointestinal symptoms, primarily nausea."

This trial shows that semaglutide's effect starts at low exposures and climbs unevenly. It does not show that a small once-weekly dose works, because the weekly totals in even the smallest arm sat above what microdosing protocols use. Our article on low dose semaglutide for weight loss goes through the semaglutide trials dose by dose.

Does microdose tirzepatide work?

Microdose tirzepatide has not been tested for weight loss either, but tirzepatide does have one trial arm below its label: 1 mg once weekly. The phase 2 trial by Frias and colleagues, published in the Lancet in 2018, randomized 318 adults with type 2 diabetes to tirzepatide 1 mg, 5 mg, 10 mg or 15 mg weekly, dulaglutide 1.5 mg, or placebo for 26 weeks.

HbA1c fell 1.06% on 1 mg, 1.73% on 5 mg, 1.89% on 10 mg and 1.94% on 15 mg, compared with 0.06% on placebo and 1.21% on dulaglutide. Body weight changes across the four tirzepatide doses ranged from -0.9 kg to -11.3 kg, against -0.4 kg on placebo and -2.7 kg on dulaglutide. Between 14% and 71% of people on tirzepatide reached at least 5% weight loss, depending on dose.

Read plainly, 1 mg of tirzepatide had a real effect on blood sugar in people with diabetes. The abstract reports weight only as a range across doses, and the bottom of that range was under a kilogram. That is a narrow finding from a 26-week study in a different population from most people asking about microdoses.

How do side effects compare at low doses?

Side effects of both drugs rise with dose, and the lowest doses tested carry the fewest. The clearest tirzepatide data come from the same phase 2 trial, which reported that gastrointestinal events were dose-related.

Gastrointestinal events affected 23.1% on 1 mg, 32.7% on 5 mg, 51.0% on 10 mg and 66.0% on 15 mg, against 42.6% on dulaglutide and 9.8% on placebo. Decreased appetite was reported by 3.8% on 1 mg and 20.0% on 5 mg, compared with 2.0% on placebo. That jump between 1 mg and 5 mg is one of the few data points that hints at where tirzepatide's appetite effect starts to show.

In the head-to-head SURPASS-2 trial, digestive side effects were similar between the drugs at the doses tested: nausea affected 17 to 22% on tirzepatide and 18% on semaglutide 1 mg, and vomiting 6 to 10% versus 8%. Serious adverse events were reported in 5 to 7% on tirzepatide and 3% on semaglutide. Our guide to whether microdosing Ozempic is safe covers the label warnings that apply at every dose.

Microdose semaglutide vs tirzepatide: which is better?

At microdoses, neither semaglutide nor tirzepatide can be called better, because the comparison has never been made. At labeled doses, tirzepatide consistently produced more weight loss. Three trials frame that gap.

The first is SURMOUNT-1, by Jastreboff and colleagues in the New England Journal of Medicine in 2022. It gave 2539 adults without diabetes tirzepatide 5 mg, 10 mg or 15 mg or placebo for 72 weeks, from a mean starting weight of 104.8 kg.

Weight fell 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo, and 85% of people on 5 mg lost at least 5% of their weight. Adverse events caused people to stop in 4.3% on 5 mg, 7.1% on 10 mg and 6.2% on 15 mg, versus 2.6% on placebo. The lowest maintenance dose gave most of the benefit with the fewest dropouts.

The second is SURPASS-2, by Frías and colleagues in the New England Journal of Medicine in 2021. It is the only head-to-head trial that pitted tirzepatide against a lower semaglutide dose: 1879 people with type 2 diabetes received tirzepatide 5 mg, 10 mg or 15 mg or semaglutide 1 mg weekly for 40 weeks.

Tirzepatide led to 1.9 kg, 3.6 kg and 5.5 kg more weight loss than semaglutide 1 mg at the three doses. HbA1c fell 2.01, 2.24 and 2.30 percentage points on tirzepatide and 1.86 on semaglutide.

The third is SURMOUNT-5, by Aronne and colleagues in the New England Journal of Medicine in 2025. It randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks.

Weight fell 20.2% on tirzepatide and 13.7% on semaglutide, and waist circumference 18.4 cm versus 13.0 cm. In both groups the most common adverse events were digestive, mostly mild to moderate, and occurred "primarily during dose escalation." None of these trials says the gap holds at a fraction of the starting dose. The ranking could hold, shrink or flip at microdoses; the data simply stop.

How long does each drug stay in the body?

Semaglutide stays in the body slightly longer than tirzepatide. The Wegovy label gives semaglutide an elimination half-life of approximately 1 week and says it remains in circulation for about 5 to 7 weeks after the last injection. The Zepbound label gives tirzepatide a half-life of approximately 5-6 days in people with overweight or obesity.

Long half-lives are why weekly dosing works for both, and why small weekly doses build up gradually instead of holding steady from the first week. They also mean a dose change takes weeks to show its full effect, and side effects can linger after stopping. Our article on weekly versus split dosing works through what that half-life math means for dose timing.

Does microdose semaglutide need to be refrigerated?

Yes. Semaglutide needs refrigeration whatever the dose, and so does tirzepatide. A smaller dose does not make the protein more stable. Both labels call for storage at 2°C to 8°C and say not to freeze the medicine.

A Wegovy single-dose pen can be kept between 8°C and 30°C (46°F to 86°F) for up to 28 days before the cap comes off. Zepbound single-dose pens and vials can be unrefrigerated at no more than 30°C (86°F) for up to a total of 21 days. Compounded vials carry their own beyond-use dates, set by the pharmacy, and the label figures above do not apply to them.

How do people get microdose semaglutide or tirzepatide?

Both drugs are prescription-only, so any microdose starts with a licensed prescriber. Branded pens deliver set doses, starting at 0.25 mg for Wegovy and 2.5 mg for Zepbound, so doses below those usually come from compounded vials that a pharmacy prepares.

The FDA's page on unapproved GLP-1 drugs states that compounded drugs are not FDA approved and that the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed." It also describes dosing errors in which patients measured and self-injected the wrong amount, some requiring hospitalization. As of May 31, 2026, the FDA had received 990 adverse event reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide. Small doses drawn from multi-dose vials leave little margin for a measuring mistake.

What is the bottom line?

The microdose semaglutide vs tirzepatide question has no trial answer yet. Semaglutide has the better low-dose evidence, from a daily dose-ranging study. Tirzepatide has a single 1 mg weekly arm that lowered blood sugar with modest weight change and few side effects. At labeled doses tirzepatide wins on weight loss, but that result says nothing reliable about a fraction of the starting dose. Anyone choosing between them at small doses is working from extrapolation, and the choice of drug, dose and source belongs with a prescriber.

Frequently asked questions

Clinical references

1. O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018. doi:10.1016/S0140-6736(18)31773-2
2. Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018. doi:10.1016/S0140-6736(18)32260-8
3. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021. doi:10.1056/NEJMoa2107519
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022. doi:10.1056/NEJMoa2206038
5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2416394
6. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, National Library of Medicine. Accessed October 12, 2026. dailymed.nlm.nih.gov
7. WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, National Library of Medicine. Accessed October 12, 2026. dailymed.nlm.nih.gov
8. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Accessed October 12, 2026. fda.gov